|
[1]BURZA MA, MARSCHALL HU, NAPOLEONE L, et al.The 35-year odyssey of beta blockers in cirrhosis:any gender difference in sight?[J].Pharmacol Res, 2017, 119:20-26.
|
|
[2]VOROBIOFF JD, GROSZMANN RJ.Prevention of portal hypertension:from variceal development to clinical decompensation[J].Hepatology, 2015, 61 (1) :375-381.
|
|
[3]BRU7) HA R, PETRTY'L J.Evaluation and treatment of portal hypertension[J].Cas Lek Cesk, 2016, 155 (2) :22-26.
|
|
[4]BRUNNER F, BERZIGOTTI A, BOSCH J.Prevention and treatment of variceal haemorrhage in 2017[J].Liver Int, 2017, 37 (Suppl 1) :104-115.
|
|
[5]NEUGEBAUER G, AKPAN W, von MOLLENDORFF E, et al.Pharmacokinetics and disposition of carvedilol in humans[J].J Cardiovasc Pharmacol, 1987, 10 (Suppl 11) :s85-s88.
|
|
[6]ALVES JM, PRADO LD, ROCHA HV.Evaluation and correlation of the physicochemical properties of carvedilol[J].Pharm Dev Technol, 2016, 21 (7) :856-866.
|
|
[7]HONDA M, OGURA Y, TOYODA W, et al.Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54healthy Japanese volunteers[J].Biol Pharm Bull, 2006, 29 (4) :772-778.
|
|
[8]TAKEKUMA Y, YAGISAWA K, SUGAWARA M.Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes[J].Biol Pharm Bull, 2012, 35 (2) :151-163.
|
|
[9]ASHKENAZI E, KOVALEV Y, ZUCKERMAN E.Evaluation and treatment of esophageal varices in the cirrhotic patient[J].Isr Med Assoc J, 2013, 15 (2) :109-115.
|
|
[10]GUPTA V, RAWAT R, SHALIMAR, et al.Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed:RCT[J].Hepatol Int, 2017, 11 (2) :181-187.
|
|
[11]ABID S, ALI S, BAIG MA, et al.Is it time to replace propranolol with carvedilol for portal hypertension?[J].World J Gastrointest Endosc, 2015, 7 (5) :532-539.
|
|
[12]SINAGRA E, PERRICONE G, D'AMICO M, et al.Systematic review with meta-analysis:the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J].Aliment Pharmacol Ther, 2014, 39 (6) :557-568.
|
|
[13]BHARDWAJ A, KEDARISETTY CK, VASHISHTHA C, et al.Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis:a randomised placebo-controlled trial[J].Gut, 2017, 66 (10) :1838-1843.
|
|
[14]WADHAWAN M, DUBEY S, SHARMA BC, et al.Hepatic venous pressure gradient in cirrhosis:correlation with the size of varices, bleeding, ascites, and child's status[J].Dig Dis Sci, 2006, 51 (12) :2264-2269.
|
|
[15]SARIN SK, MISHRA SR, SHARMA P, et al.Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis:a randomized controlled trial[J].Hepatol Int, 2013, 7 (1) :248-256.
|
|
[16]EL-DEMERDASH E, ABDEL-SATTAR SA, EL-BAKLY WM, et al.Antifibrotic effects of carvedilol and impact of liver fibrosis on carvedilol pharmacokinetics in a rat model[J].Eur J Drug Metab Pharmacokinet, 2017, 42 (5) :767-779.
|
|
[17]ARAU'JO JU'NIOR RF, GARCIA VB, LEITAO RF, et al.Carvedilol improves inflammatory response, oxidative stress and fibrosis in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells[J].PLo S One, 2016, 11 (2) :e0148868.
|
|
[18]KAZEMI F, KETTANEH A, N'KONTCHOU G, et al.Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices[J].J Hepatol, 2006, 45 (2) :230-235.
|
|
[19]REIBERGER T, FERLITSCH A, PAYER BA, et al.Non-selectiveβ-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis[J].J Gastroenterol, 2012, 47 (5) :561-568.
|
|
[20]AUGUSTIN S, PONS M, MAURICE JB, et al.Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease[J].Hepatology, 2017.[Epub ahead of print]
|
|
[21]REIBERGER T, ULBRICH G, FERLITSCH A, et al.Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J].Gut, 2013, 62 (11) :1634-1641.
|
|
[22]KIM SG, KIM TY, SOHN JH, et al.A randomized, multi-center, open-label study to evaluate the efficacy of carvedilol vs.propranolol to reduce portal pressure in patients with liver cirrhosis[J].Am J Gastroenterol, 2016, 111 (11) :1582-1590.
|
|
[23]AGARWALA V, PRAKASH G, SINGH R, et al.Evaluation of treatment with carvedilol in comparison to propranolol in primary/secondary prophylaxis of gastroesophageal variceal bleeding[J].Indian J Gastroenterol, 2011, 30 (Suppl 1) :a46.
|
|
[24]BANRES R, MOITINHO E, MATILLA A, et al.Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J].Hepatology, 2002, 36 (6) :1367-1373.
|
|
[25]HOBOLTH L, MØLLER S, GRØNBÆK H, et al.Carvedilol or propranolol in portal hypertension?A randomized comparison[J].Scand J Gastroenterol, 2012, 47 (4) :467-474.
|
|
[26]LO GH.Did carvedilol really have more severe adverse events than propranolol in cirrhotic patients?[J].Am J Gastroenterol, 2017, 112 (5) :808.
|
|
[27]TRIPATHI D, FERGUSON JW, KOCHAR N, et al.Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed[J].Hepatology, 2009, 50 (3) :825-833.
|
|
[28]TRIANTOS C, VLACHOGIANNAKOS J, ARMONIS A, et al.Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers:a randomized trial of ligation[J].Aliment Pharmacol Ther, 2005, 21 (12) :1435-1443.
|
|
[29]SHRESTHA B, KC S, CHAUDHARY S, et al.Outcome of endoscopic variceal band ligation[J].JNMA J Nepal Med Assoc, 2017, 56 (206) :198-202.
|
|
[30]WANI ZA, BAHT RA, BHADORIA AS, et al.After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis?[J].Saudi J Gastroenterol, 2015, 21 (5) :278-283.
|
|
[31]RASOOL MF, KHALIL F, LAER S.Optimizing the clinical use of carvedilol in liver cirrhosis using a physiologically based pharmacokinetic modeling approach[J].Eur J Drug Metab Pharmacokinet, 2017, 42 (3) :383-396.
|
|
[32]TRIPATHI D, STANLEY AJ, HAYES PC, et al.U.K.guidelines on the management of variceal haemorrhage in cirrhotic patients[J].Gut, 2015, 64 (11) :1680-1704.
|
|
[33]KIRNAKE V, ARORA A, GUPTA V, et al.Hemodynamic response to carvedilol is maintained for long periods and leads to better clinical outcome in cirrhosis:a prospective study[J].J Clin Exp Hepatol, 2016, 6 (3) :175-185.
|
|
[34]LAY CS, TSAI YT, LEE FY, et al.Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis[J].J Gastroenterol Hepatol, 2006, 21 (2) :413-419.
|
|
[35]ONALI S, KALAFATELI M, MAJUMDAR A, et al.Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites[J].Liver Int, 2017, 37 (9) :1334-1344.
|
|
[36]THORHAUGE KH, LINDVIG KP, LALEMAN W, et al.Lack of consensus for usage of beta-blockers in end-stage liver disease[J].Gut, 2016, 65 (6) :1058-1060.
|
|
[37]MANDORFER M, REIBERGER T.Beta blockers and cirrhosis, 2016[J].Dig Liver Dis, 2017, 49 (1) :3-10.
|
DownLoad: